National Institutes of Health, Public Health Service, HHS.
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive license to practice the inventions embodied in:
1. U.S. Provisional Patent Application Serial No. 60/576,056, filed on June 1, 2004, entitled “Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use”, converted to PCT/US2005/18778, filed May 27, 2005, and entered national stage in U.S. (patent application serial number 11/569,813), Canada (patent application serial number 2,567,728), Australia (patent application serial number 2005250429), Europe (patent application serial number 05804849.7), Japan (patent application serial number 2007-515398), Israel (patent application serial number 179236), New Zealand (patent number 2006/09573), and South Africa (patent application serial number 2006/09573) (HHS reference E-106-2003/0) from Dr. Barry O'Keefe et al. (NCI).
2. U.S. Provisional Patent Application Serial No. 60/741.403, filed on Start Printed Page 48356December 1, 2005, entitled “Antiviral Activity Of Griffithsin Against SARS And HCV”, converted to PCT/US2006/045930, filed December 1, 2006, and entered national stage in U.S. (patent application serial number 12/095,697), and Europe (patent application serial number 06838737.2) (HHS reference E-025-2006/0) from Dr. Barry O'Keefe et al. (NCI).
To Rodos Biotarget GmbH (Rodos here after) having a place of business in Germany. The patent rights in these inventions have been assigned to the United States of America.
Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before September 9, 2010 will be considered.
Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Sally Hu, PhD, M.B.A., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; E-mail: firstname.lastname@example.org; Telephone: (301) 435-5606; Facsimile: (301) 402-0220.End Preamble Start Supplemental Information
The first invention, E-106-2003, provides for isolated and purified Griffithsin protein and antibodies, plus related purified nucleic acids. Griffithsin is a novel, potent anti-HIV protein isolated from an aqueous extract of the red algae Griffithsia and Griffithsin inhibits viral binding, fusion and entry into the host cells by binding to viral envelope gp120. In addition, E-106-2003 also provides the methods of producing Griffithsin and methods of inhibiting a viral infection (incl. HIV), as well as vaccine development, and screening assays.
The second invention, E-025-2006, follows its predecessor patent application (E-106-2003) and claims new indications in particular for severe acute respiratory syndrome (SARS) and Hepatitis C. More specifically, the subject invention provides for a composition of an anti-viral polypeptide, Griffithsin, glycosylation-resistant Griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, antibodies and methods of production and use.
Based on the above two inventions, Griffithsin can be developed as an HIV entry inhibitor therapeutically or prophylactically against retroviral infections and also can be developed as an inhibitor against non-retroviruses infectious such as influenza virus, including H5N1, SARS, Hepatitis C, and Ebola, measles, varicella, human herpes viruses and others. In addition, Griffithsin can be used in combination with other anti-viral agents to treat patients who have drug-resistant virus.
The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 30 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license will enter an agreement with University of Canterbury in Christchurch of New Zealand complying with the U.S. Government's policy of the U.N. CBD for sharing in a fair and equitable way the results of research and development and the benefits arising from the commercial and other utilization of genetic researches with the “Source Country” providing such resources (U.N. CBD; Article 15.7: http://www.cbd.int/convention/convention.shtml).
The field of use may be limited to the development of non-encapsulated and encapsulated Griffithsin for use in treating human viral infections where those viral infections are human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.Start Signature
Dated: August 3, 2010 .
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. 2010-19680 Filed 8-9-10; 8:45 am]
BILLING CODE 4140-01-P